Trial Profile

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels vs Placebo When Administered to Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD).

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aclidinium bromide (Primary)
Indications Chronic obstructive pulmonary disease
Focus Registrational; Therapeutic Use
Acronyms ATTAIN
Sponsors Almirall S.A.

Most Recent Events

22 May 2013 Results presented at the 109th International Conference of the American Thoracic Society.
05 Sep 2012 Effects of treatment on disease exacerbations presented at the 22nd Annual Congress of the European Respiratory Society.
22 Mar 2012 Full results were published in the European Respiratory Journal, according to a Almirall media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com